OA12393A - Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same. - Google Patents

Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same. Download PDF

Info

Publication number
OA12393A
OA12393A OA1200300003A OA1200300003A OA12393A OA 12393 A OA12393 A OA 12393A OA 1200300003 A OA1200300003 A OA 1200300003A OA 1200300003 A OA1200300003 A OA 1200300003A OA 12393 A OA12393 A OA 12393A
Authority
OA
OAPI
Prior art keywords
activity
target tissue
prodrug
pmpa
alkyl
Prior art date
Application number
OA1200300003A
Other languages
English (en)
Inventor
Mark W Becker
Harlan H Chapman
Tomas Cihlar
Eugene J Eisenberg
Gong-Xin He
Michael R Kernan
Ernest J Prisbe
John C Rohloff
Mark L Sparacino
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22821718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA12393(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of OA12393A publication Critical patent/OA12393A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18Testing for antimicrobial activity of a material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
OA1200300003A 2000-07-21 2001-07-20 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same. OA12393A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22002100P 2000-07-21 2000-07-21

Publications (1)

Publication Number Publication Date
OA12393A true OA12393A (en) 2006-04-18

Family

ID=22821718

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200300003A OA12393A (en) 2000-07-21 2001-07-20 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.

Country Status (37)

Country Link
US (10) US20020119443A1 (pm)
EP (3) EP2682397B1 (pm)
JP (4) JP4651264B2 (pm)
KR (2) KR100767432B1 (pm)
CN (2) CN100402539C (pm)
AP (1) AP1466A (pm)
AU (3) AU2001282941C1 (pm)
BE (1) BE2016C018I2 (pm)
BG (1) BG66037B1 (pm)
BR (1) BRPI0112646B8 (pm)
CA (3) CA2416757C (pm)
CY (2) CY2016008I1 (pm)
CZ (2) CZ304886B6 (pm)
DK (2) DK2682397T3 (pm)
EA (1) EA004926B1 (pm)
EE (1) EE05366B1 (pm)
ES (2) ES2627903T3 (pm)
FR (1) FR16C0013I2 (pm)
HK (1) HK1243711A1 (pm)
HR (2) HRP20030047B1 (pm)
HU (2) HU230960B1 (pm)
IL (1) IL153658A0 (pm)
IS (1) IS2985B (pm)
LT (2) LT2682397T (pm)
LU (1) LU93029I2 (pm)
MX (1) MXPA03000587A (pm)
NL (1) NL300803I2 (pm)
NO (6) NO336718B1 (pm)
NZ (3) NZ535408A (pm)
OA (1) OA12393A (pm)
PL (1) PL213214B1 (pm)
PT (2) PT2682397T (pm)
SI (2) SI1301519T1 (pm)
TR (1) TR200300055T2 (pm)
UA (1) UA75889C2 (pm)
WO (1) WO2002008241A2 (pm)
ZA (1) ZA200210271B (pm)

Families Citing this family (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL153658A0 (en) * 2000-07-21 2003-07-06 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
EA200400690A1 (ru) * 2001-11-14 2005-06-30 Байокрист Фармасьютикалз, Инк. Нуклеозиды, их препараты и их применение в качестве ингибиторов вирусных рнк-полимераз
US7388002B2 (en) * 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US20050239054A1 (en) * 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
TWI332956B (en) * 2002-04-26 2010-11-11 Gilead Sciences Inc Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds
EP1532157A4 (en) 2002-05-13 2009-02-25 Metabasis Therapeutics Inc NEW PRODRUGS FROM PMEA TO PHOSPHONIC ACID BASE AND ITS ANALOG
KR20080032014A (ko) 2003-01-14 2008-04-11 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
CN101410120A (zh) * 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7300924B2 (en) * 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
DK1628685T3 (da) * 2003-04-25 2011-03-21 Gilead Sciences Inc Antivirale phosphonatanaloge
WO2005002626A2 (en) * 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
WO2005047898A2 (en) * 2003-10-24 2005-05-26 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
US7417055B2 (en) 2003-04-25 2008-08-26 Gilead Sciences, Inc. Kinase inhibitory phosphonate analogs
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
DE602004019815D1 (de) * 2003-12-22 2009-04-16 Gilead Sciences Inc 4'-substituierte carbovir- und abacavir-derivate sowie verwandte verbindungen mit hiv- und hcv-antiviraler wirkung
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
BRPI0418031A (pt) * 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
ES2389602T3 (es) * 2003-12-30 2012-10-29 Gilead Sciences, Inc. Fosfonatos de nucleósidos y análogos de los mismos para el tratamiento de infecciones por el VPH
ES2334149T3 (es) * 2004-01-21 2010-03-05 Gilead Sciences, Inc. Uso de adefovir o tenofovir para inhibir virus de tipo vtmr implicados en el cancer de mama y en la cirrosis biliar primaria.
US8416242B1 (en) 2004-05-14 2013-04-09 Nvidia Corporation Method and system for interpolating level-of-detail in graphics processors
US8432394B1 (en) 2004-05-14 2013-04-30 Nvidia Corporation Method and system for implementing clamped z value interpolation in a raster stage of a graphics pipeline
US8411105B1 (en) 2004-05-14 2013-04-02 Nvidia Corporation Method and system for computing pixel parameters
US7079156B1 (en) 2004-05-14 2006-07-18 Nvidia Corporation Method and system for implementing multiple high precision and low precision interpolators for a graphics pipeline
EP1753762B1 (en) 2004-06-08 2014-03-19 Metabasis Therapeutics, Inc. Lewis acid mediated synthesis of cyclic esters
HRP20110527T1 (hr) 2004-07-27 2011-08-31 Gilead Sciences Nukleozid-fosfonatni konjugati kao sredstva protiv hiv-a
US20070003608A1 (en) * 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of viral infections and other medical disorders
EP1868628B1 (en) 2005-04-08 2014-06-11 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
CN100359315C (zh) * 2005-05-26 2008-01-02 林维宣 兽药残留能力验证样品及制备方法
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN100396689C (zh) * 2006-03-07 2008-06-25 中国医学科学院医药生物技术研究所 一组具有抑制hiv-1/hbv病毒复制活性的替诺福韦单酯化合物
JP5544165B2 (ja) 2006-05-16 2014-07-09 ギリアード サイエンシーズ, インコーポレイテッド 血液悪性疾患の処置のための方法および組成物
WO2008007392A2 (en) * 2006-07-12 2008-01-17 Matrix Laboratories Limited Process for the preparation of tenofovir
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009038851A2 (en) * 2007-06-26 2009-03-26 University Of Wyoming Research Corporation D/B/A Western Research Institute Treatment and prevention systems for acid mine drainage and halogenated contaminants
US8441497B1 (en) * 2007-08-07 2013-05-14 Nvidia Corporation Interpolation of vertex attributes in a graphics processor
ES2572631T3 (es) * 2008-01-25 2016-06-01 Chimerix, Inc. Métodos de tratamiento de infecciones virales
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
WO2009130437A1 (en) * 2008-04-25 2009-10-29 Cipla Limited Crystalline form of tenofovir disoproxil and a process for its preparation
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
ES2458358T3 (es) * 2008-07-02 2014-05-05 Idenix Pharmaceuticals, Inc. Compuestos y composiciones farmacéuticas para el tratamiento de infecciones víricas
NZ590075A (en) * 2008-07-08 2012-12-21 Gilead Sciences Inc citrate, malonate and succinate salts of the HIV inhibitor ethyl N-[(S)({ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy} methyl)phenoxyphosphinoyl]-L-alaninate
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
KR20110099138A (ko) 2008-12-23 2011-09-06 파마셋 인코포레이티드 뉴클레오시드 포스포르아미데이트
TW201026716A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside analogs
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
JP5767643B2 (ja) 2009-09-21 2015-08-19 ギリード・サイエンシズ・インコーポレーテッド 1’−置換カルバヌクレオシド類似体の調製のためのプロセスおよび中間体
HUE032860T2 (en) 2010-02-12 2017-11-28 Chimerix Inc A method for treating a virus infection
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
EP2752422B1 (en) 2010-03-31 2017-08-16 Gilead Pharmasset LLC Stereoselective synthesis of phosphorus containing actives
JP2013523765A (ja) 2010-04-01 2013-06-17 イデニク プハルマセウティカルス,インコーポレイテッド ウイルス感染の治療のための化合物及び医薬組成物
WO2011139709A2 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
PH12013500033A1 (en) 2010-07-19 2017-07-26 Gilead Sciences Inc Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
PE20171155A1 (es) 2010-07-22 2017-08-16 Gilead Sciences Inc Metodos y compuestos para tratar infecciones virales por paramyxoviridae
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
MX2013006127A (es) 2010-12-10 2013-09-26 Sigmapharm Lab Llc Composiciones sumamente estables de analogos nucleotidicoas oralmente activos o profarmacos analogos nucleotidicos oralmente activos.
ZA201103820B (en) 2010-12-13 2012-01-25 Laurus Labs Private Ltd Process for the preparation of tenofovir
JP2014514295A (ja) 2011-03-31 2014-06-19 アイディニックス ファーマシューティカルズ インコーポレイテッド ウイルス感染の治療のための化合物および薬学的組成物
WO2012154698A2 (en) * 2011-05-06 2012-11-15 Mckenna Charles E Method to improve antiviral activity of nucleotide analogue drugs
CA2835932C (en) 2011-05-19 2020-03-24 Gilead Sciences, Inc. Processes and intermediates for preparing anti-hiv agents
US8754065B2 (en) * 2011-08-16 2014-06-17 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
AU2014271320B2 (en) * 2011-08-16 2017-02-23 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
UA116087C2 (uk) 2011-09-16 2018-02-12 Гіліад Фармассет Елелсі Композиція для лікування вірусу гепатиту c
AU2016228317B2 (en) * 2011-10-07 2018-07-19 Gilead Sciences, Inc. Methods for preparing anti-viral nucleotide analogs
TWI689513B (zh) * 2011-10-07 2020-04-01 美商基利科學股份有限公司 抗病毒核苷酸類似物的製備方法
AU2014215976B2 (en) * 2011-10-07 2016-06-30 Gilead Sciences, Inc. Methods for preparing anti-viral nucleotide analogs
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9593137B2 (en) 2011-12-22 2017-03-14 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
KR20140119177A (ko) 2012-02-03 2014-10-08 길리애드 사이언시즈, 인코포레이티드 바이러스 감염의 치료에 사용하기 위한 테노포비르 알라페나미드 헤미푸마레이트 및 코비시스타트를 포함하는 조합 요법
AU2012327170A1 (en) 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
GB201215696D0 (en) * 2012-09-03 2012-10-17 Ithemba Pharmaceuticals Pty Ltd A process for the preparation of (R)-9-[2-(Phosphonometh-Oxy)propyl]adenine (PMPA)
EP2912047B1 (en) 2012-10-29 2016-08-24 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CN102899327B (zh) * 2012-11-06 2014-06-11 清华大学深圳研究生院 一种抗病毒的小核酸及其温度敏感型凝胶制剂与应用
CN104918939B (zh) * 2012-11-16 2018-08-28 默沙东公司 人磷脂酰肌醇3-激酶δ的嘌呤抑制剂
CN103848869B (zh) * 2012-12-04 2016-12-21 上海医药工业研究院 制备替诺福韦的方法
CN103848868B (zh) * 2012-12-04 2017-04-12 蚌埠丰原涂山制药有限公司 制备替诺福韦的方法
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CN104072539B (zh) * 2013-03-25 2017-03-29 安徽贝克联合制药有限公司 替诺福韦双(4‑乙酰氨基苯酚氧基)酯及其制备方法和其应用
JP6262848B2 (ja) * 2013-05-21 2018-01-17 成都先導薬物開発有限公司 薬物標的の捕獲方法
IN2013MU01967A (pm) 2013-06-07 2015-06-12 Cipla Ltd
ES2792503T3 (es) 2013-08-27 2020-11-11 Gilead Pharmasset Llc Formulación combinada de dos compuestos antivirales
WO2015040640A2 (en) * 2013-09-20 2015-03-26 Laurus Labs Private Limited An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
EP2860185A1 (en) 2013-10-09 2015-04-15 Zentiva, k.s. An improved process for the preparation of Tenofovir disoproxil and pharmaceutically acceptable salts thereof
WO2015079455A2 (en) * 2013-11-27 2015-06-04 Laurus Labs Private Limited A recycling process for preparing tenofovir alafenamide diastereomers
EP3077404B1 (en) * 2014-01-14 2020-10-07 Mylan Laboratories Ltd. Purification of tenofovir alafenamide and its intermediates
TWI660965B (zh) 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
CN104804042B (zh) * 2014-01-24 2018-01-19 齐鲁制药有限公司 核苷酸膦酸酯类化合物、其药物组合物、制备方法及用途
WO2015120057A1 (en) 2014-02-05 2015-08-13 Gilead Sciences, Inc. Pharmaceutical combinations against co-infection with hiv and tuberculosis
US10449210B2 (en) * 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
WO2015127848A1 (zh) * 2014-02-27 2015-09-03 四川海思科制药有限公司 一种取代的氨基磷酸酯类衍生物、其制备方法及其应用
CN105001262B (zh) * 2014-04-18 2017-09-01 四川海思科制药有限公司 芳基取代的磷酰胺类衍生物及其在医学上的应用
WO2015161785A1 (zh) * 2014-04-21 2015-10-29 四川海思科制药有限公司 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法
CN105085571A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 替诺福韦艾拉酚胺复合物及其制备方法和用途
CN105518012B (zh) * 2014-06-25 2018-03-02 四川海思科制药有限公司 一种取代的氨基酸硫酯类化合物、其组合物及应用
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
PL3194411T3 (pl) 2014-09-15 2022-06-20 The Regents Of The University Of California Analogi nukleotydów
KR101703258B1 (ko) 2014-12-30 2017-02-06 한미정밀화학주식회사 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법
JP2017535520A (ja) * 2014-09-30 2017-11-30 ハンミ・ファイン・ケミカル・カンパニー・リミテッドHanmi Fine Chemical Co., Ltd. 高純度の(r)−9−[2−(ホスホノメトキシ)プロピル]アデニンの製造方法
KR101703257B1 (ko) 2014-09-30 2017-02-06 한미정밀화학주식회사 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
CN105646584B (zh) * 2014-11-12 2018-09-28 四川海思科制药有限公司 替诺福韦艾拉酚胺富马酸盐晶型及其制备方法和用途
CN104558036A (zh) * 2014-12-11 2015-04-29 杭州和泽医药科技有限公司 一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法
WO2016108205A1 (en) 2015-01-03 2016-07-07 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
US20180148774A1 (en) * 2015-05-16 2018-05-31 Godx, Inc Point of need testing device and methods of use thereof
CN106188139B (zh) * 2015-05-29 2020-02-18 江苏天士力帝益药业有限公司 替诺福韦单苄酯磷酸酰胺前药、其制备方法及应用
CZ2015384A3 (cs) 2015-06-05 2016-12-14 Zentiva, K.S. Pevné formy Tenofovir alafenamidu
WO2016205141A1 (en) * 2015-06-17 2016-12-22 Gilead Sciences, Inc. Co-crystals, salts and solid forms of tenofovir alafenamide
HK1248547A1 (zh) 2015-06-30 2018-10-19 吉利德科学公司 包含替诺福韦和恩曲他滨的药物制剂
KR102163611B1 (ko) 2015-08-10 2020-10-08 머크 샤프 앤드 돔 코포레이션 항바이러스 베타-아미노산 에스테르 포스포디아미드 화합물
TWI620754B (zh) * 2015-08-26 2018-04-11 Method for preparing amino phosphate derivative and preparation method thereof
TWI616452B (zh) * 2015-08-26 2018-03-01 Preparation method of nucleoside analog and intermediate thereof
TWI616453B (zh) * 2015-08-27 2018-03-01 Substituted amino acid thioester compounds, compositions and uses thereof
WO2017037608A1 (en) * 2015-08-28 2017-03-09 Laurus Labs Private Limited Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof
ES2918585T3 (es) 2015-09-16 2022-07-19 Gilead Sciences Inc Métodos para el tratamiento de infecciones por el virus Arenaviridae
BR102016026127A2 (pt) 2015-11-09 2017-05-16 Gilead Sciences Inc composições terapêuticas para o tratamento do vírus da imunodeficiência humana
CN106800573B (zh) * 2015-11-25 2020-03-10 四川海思科制药有限公司 一种核苷酸膦酸酯一水合物及其制备方法和在医药上的应用
EP3386512B1 (en) 2015-12-10 2023-11-22 Merck Sharp & Dohme LLC Antiviral phosphodiamide prodrugs of tenofovir
CN106866737B (zh) * 2015-12-11 2020-11-20 南京圣和药物研发有限公司 膦酸衍生物及其应用
WO2017106069A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
WO2017118928A1 (en) 2016-01-06 2017-07-13 Lupin Limited Process for the separation of diastereomers of tenofovir alafenamide
WO2017134089A1 (en) 2016-02-02 2017-08-10 Sandoz Ag Crystalline forms of tenofovir alafenamide monofumarate
WO2017133517A1 (zh) * 2016-02-03 2017-08-10 四川海思科制药有限公司 一种磷酰胺衍生物及制备方法和用途
CN108350007B (zh) * 2016-03-01 2020-04-10 深圳市塔吉瑞生物医药有限公司 一种取代的腺嘌呤化合物及其药物组合物
CN107179355B (zh) * 2016-03-11 2021-08-10 广东东阳光药业有限公司 一种分离检测替诺福韦艾拉酚胺及其有关物质的方法
CZ2016156A3 (cs) 2016-03-17 2017-09-27 Zentiva, K.S. Způsob přípravy diastereomerně čistého Tenofoviru Alafenamidu nebo jeho solí
CN107226826A (zh) * 2016-03-25 2017-10-03 江苏奥赛康药业股份有限公司 替诺福韦艾拉酚胺富马酸盐化合物及其药物组合物
WO2017211325A1 (zh) * 2016-06-05 2017-12-14 上海诚妙医药科技有限公司 富马酸替诺福韦艾拉酚胺盐的新晶型、制备方法及其用途
CN107698621A (zh) * 2016-06-20 2018-02-16 杭州和泽医药科技有限公司 一种腺嘌呤衍生物的膦酸酯前药及其在医药上的应用
WO2017221189A1 (en) * 2016-06-22 2017-12-28 Laurus Labs Limited An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
ES2954514T3 (es) 2016-08-19 2023-11-22 Gilead Sciences Inc Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del VIH
CN106317116A (zh) * 2016-08-19 2017-01-11 张红利 磷酰胺核苷类化合物及其药学上可接受的盐与应用、药物组合物
US10449208B2 (en) 2016-08-25 2019-10-22 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
CN106380484A (zh) * 2016-08-29 2017-02-08 杭州百诚医药科技股份有限公司 一种替诺福韦艾拉酚胺的新晶型及其制备方法
WO2018042331A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018051250A1 (en) 2016-09-14 2018-03-22 Viiv Healthcare Company Combination comprising tenofovir alafenamide, bictegravir and 3tc
EP3532069A4 (en) 2016-10-26 2020-05-13 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
CN106565785B (zh) * 2016-11-09 2019-11-12 周雨恬 一种具有抗hbv/hiv活性的核苷氨基磷酸酯类化合物及其盐和用途
CN108129514A (zh) * 2016-12-01 2018-06-08 北京美倍他药物研究有限公司 磷酸/膦酸衍生物的单一异构体及其医药用途
BR112019012511A2 (pt) * 2016-12-22 2019-11-19 Idenix Pharmaceuticals Llc compostos antivirais de benzil-amina fosfodiamida, composição farmacêutica e uso do composto
EP3559011B1 (en) 2016-12-22 2022-04-13 Merck Sharp & Dohme Corp. Antiviral ester prodrugs of tenofovir
WO2018115046A1 (en) 2016-12-23 2018-06-28 Sandoz Ag Crystalline solid forms of tenofovir alafenamide
TWI714820B (zh) 2017-01-31 2021-01-01 美商基利科學股份有限公司 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
WO2018153977A1 (en) 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
US20190374557A1 (en) * 2017-02-28 2019-12-12 Alexandre Vasilievich Ivachtchenko Cyclobutyl (S)-2-[[[(R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]-propanoates, and production process and application thereof
CN106866739B (zh) * 2017-03-10 2018-11-02 华东师范大学 一种(r)-1-(6-氨基-9h-嘌呤-9-基)2-苯酯的制备方法
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
US11191763B2 (en) 2017-03-20 2021-12-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HIV post-exposure prophylaxis
CN108794530A (zh) * 2017-04-26 2018-11-13 上海医药工业研究院 一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途
ES2938859T3 (es) 2017-05-01 2023-04-17 Gilead Sciences Inc Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
KR102379965B1 (ko) * 2017-05-19 2022-03-29 주식회사 종근당 테노포비르의 효율적인 제조방법
CN107266499B (zh) * 2017-06-05 2019-07-02 珠海优润医药科技有限公司 一种抗病毒化合物及其制备方法
US12090163B2 (en) 2017-06-30 2024-09-17 Cipla Limited Pharmaceutical compositions
PL3651734T3 (pl) 2017-07-11 2025-03-31 Gilead Sciences, Inc. Kompozycje zawierające inhibitor polimerazy rna i cyklodekstrynę do leczenia infekcji wirusowych
WO2019021319A1 (en) 2017-07-27 2019-01-31 Cipla Limited PHARMACEUTICAL COMPOSITIONS
ES2969496T3 (es) 2017-08-01 2024-05-20 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2- il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
CN107655987B (zh) * 2017-09-08 2020-11-03 厦门蔚扬药业有限公司 一种替诺福韦艾拉酚胺及其异构体的hplc检测方法
CN107522743A (zh) * 2017-09-30 2017-12-29 深圳科兴生物工程有限公司 一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法
EP3700573A1 (en) 2017-10-24 2020-09-02 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
CN109942632B (zh) * 2017-12-20 2021-08-31 上海博志研新药物研究有限公司 替诺福韦艾拉酚胺中间体的制备方法
CN109942633B (zh) * 2017-12-20 2021-08-31 上海新礼泰药业有限公司 替诺福韦艾拉酚胺中间体的制备方法
US20200407382A1 (en) 2017-12-30 2020-12-31 Cipla Limited Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
CN111836818B (zh) * 2018-01-10 2023-10-31 纽科利制药公司 氨基磷(膦)酸缩醛和磷(膦)酸缩醛化合物
WO2019140365A1 (en) * 2018-01-12 2019-07-18 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
AU2019221568B2 (en) 2018-02-15 2021-04-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating HIV infection
CA3175384A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection
CN108101943B (zh) * 2018-02-28 2020-11-24 顾世海 一种替诺福韦前药或可药用盐及其在医药上的应用
WO2019199756A1 (en) 2018-04-09 2019-10-17 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
TWI814350B (zh) 2018-07-16 2023-09-01 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
US11826375B2 (en) 2018-07-19 2023-11-28 Merck Sharp & Dohme Llc Phosphinic amide prodrugs of tenofovir
US20210393631A1 (en) 2018-09-19 2021-12-23 Gilead Sciences, Inc. Integrase inhibitors for the prevention of hiv
PH12021500040A1 (en) 2019-03-22 2022-06-06 Gilead Sciences Inc Bridged tricyclic carbamolypyridone compunds and their pharmaceutical use
US12110311B2 (en) 2019-07-17 2024-10-08 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
US20220265689A1 (en) 2019-07-19 2022-08-25 THE UNITED STATES OF AMERICA , as represented by the Secretary, Department of Health and Human Hiv pre-exposure prophylaxis
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CN114502172A (zh) * 2019-08-22 2022-05-13 爱默蕾大学 核苷前药及其相关用途
EP4031141A4 (en) * 2019-09-20 2023-10-18 Abbott Rapid Diagnostics International Unlimited Company ANTIBODIES TO TENOFOVIR AND DERIVATIVES THEREOF
EP4065116A1 (en) 2019-11-26 2022-10-05 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
CN118766947A (zh) 2020-01-27 2024-10-15 吉利德科学公司 用于治疗SARS CoV-2感染的方法
WO2021165995A1 (en) 2020-02-20 2021-08-26 Cipla Limited Novel salts and/or co-crystals of tenofovir alafenamide
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ, インコーポレイテッド 4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
WO2021202669A2 (en) 2020-04-01 2021-10-07 Reyoung Corporation Nucleoside and nucleotide conjugate compounds and uses thereof
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノ置換カルバヌクレオシド類似体の吸入製剤
KR20210125298A (ko) 2020-04-08 2021-10-18 주식회사 파마코스텍 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
KR20230004716A (ko) 2020-04-21 2023-01-06 리간드 파마슈티칼스 인코포레이티드 뉴클레오티드 프로드러그 화합물
KR20230018473A (ko) 2020-05-29 2023-02-07 길리애드 사이언시즈, 인코포레이티드 렘데시비르 치료 방법
PH12022553530A1 (en) 2020-06-24 2024-06-24 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
WO2021262990A1 (en) 2020-06-25 2021-12-30 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
CN113970612B (zh) * 2020-07-22 2023-08-01 北京四环制药有限公司 一种高效液相色谱法测定丙酚替诺福韦有关物质的方法
EP4424372A3 (en) 2020-08-27 2024-12-18 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CN112336695B (zh) * 2020-09-28 2023-01-03 华北制药华坤河北生物技术有限公司 一种富马酸丙酚替诺福韦片剂及其制备方法和有关物质的检测方法
JP7659628B2 (ja) 2020-11-11 2025-04-09 ギリアード サイエンシーズ, インコーポレイテッド gp120 CD4結合部位指向性抗体による治療に感受性のHIV患者を特定する方法
US11667656B2 (en) 2021-01-27 2023-06-06 Apotex Inc. Crystalline forms of Tenofovir alafenamide
CN113075307B (zh) * 2021-03-08 2025-03-11 瑞阳制药股份有限公司 富马酸丙酚替诺福韦异构体的检测方法
CN113214322B (zh) * 2021-04-30 2022-10-25 山东立新制药有限公司 替诺福韦绿色环保的制备方法
WO2022251594A1 (en) * 2021-05-27 2022-12-01 Antios Therapeutics, Inc. Pharmacokinetics and dose-related improvments in subjects treated with phosphoramidate clevudine prodrugs
TW202342448A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於hiv病毒感染之治療性化合物
CA3238270A1 (en) 2021-12-03 2023-06-08 Gediminas J. Brizgys Therapeutic compounds for hiv virus infection
FI4445900T3 (fi) 2021-12-03 2025-08-05 Gilead Sciences Inc Terapeuttisia yhdisteitä hiv-virusinfektiota varten
CN114369120A (zh) * 2022-01-28 2022-04-19 石家庄龙泽制药股份有限公司 一种丙酚替诺福韦关键中间体的制备方法
AU2023227794A1 (en) 2022-03-02 2024-10-17 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TWI867601B (zh) 2022-07-01 2024-12-21 美商基利科學股份有限公司 可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物
JP2025526212A (ja) 2022-07-21 2025-08-13 アンティバ バイオサイエンシズ インコーポレイテッド Hpv感染症及びhpv誘発性新生物の治療用の組成物及び剤形
JP2025527677A (ja) 2022-08-26 2025-08-22 ギリアード サイエンシーズ, インコーポレイテッド 広域中和抗体のための投与及びスケジューリングレジメン
US20240226130A1 (en) 2022-10-04 2024-07-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
WO2024196814A1 (en) 2023-03-17 2024-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration
US20240390349A1 (en) 2023-04-19 2024-11-28 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
US20250122219A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250127801A1 (en) 2023-10-11 2025-04-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202515549A (zh) 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
WO2025184609A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Antiviral compounds
WO2025184452A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184447A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
CN118652277A (zh) * 2024-08-19 2024-09-17 成都工业学院 一种用于治疗癌症疾病的化合物的制备方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS233665B1 (en) 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
CS263952B1 (en) 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
CS263951B1 (en) 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5650510A (en) 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
US5057301A (en) 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US5053215A (en) * 1988-05-26 1991-10-01 University Of Florida NMR-assayable ligand-labelled trifluorothymidine containing composition and method for diagnosis of HSV infection
US5744600A (en) 1988-11-14 1998-04-28 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonomethoxy carbocyclic nucleosides and nucleotides
US5688778A (en) 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
JP2648516B2 (ja) 1989-07-27 1997-09-03 ダイセル化学工業株式会社 立体異性体の分離法
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
JP2925753B2 (ja) 1990-02-23 1999-07-28 ダイセル化学工業株式会社 光学異性体の分離方法
ATE124050T1 (de) * 1990-04-20 1995-07-15 Acad Of Science Czech Republic Chirale 2-(phosphonomethoxy)propyl-guanine als antivirale agentien.
US5302585A (en) 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
SK280313B6 (sk) 1990-04-24 1999-11-08 �Stav Organick� Chemie A Biochemie Av �R N-(3-fluór-2-fosfonylmetoxypropyl)deriváty purínov
US5627165A (en) * 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
CS276072B6 (en) 1990-08-06 1992-03-18 Ustav Organicke Chemie A Bioch (2R)-2-/DI(2-PROPYL)PHOSPHONYLMETHOXY/-3-p-TOLUENESULFONYLOXY -1- TRIMETHYLACETOXYPROPANE AND PROCESS FOR PREPARING THEREOF
EP0574386B1 (en) 1990-08-10 2000-06-28 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Novel process for the preparation of nucleotides
ATE167679T1 (de) 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5208221A (en) 1990-11-29 1993-05-04 Bristol-Myers Squibb Company Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives
CZ284678B6 (cs) 1991-05-20 1999-01-13 Ústav Organické Chemie A Biochemie Avčr Di(2-propyl)estery 1-fluor-2-fosfonomethoxy-3-p -toluensulfonyloxypropanů, způsob jejich přípravy a použití
JP3010816B2 (ja) 1991-08-22 2000-02-21 ダイセル化学工業株式会社 光学分割における光学異性体と溶媒との回収方法、溶媒の循環使用方法、および光学異性体の再利用方法
US5498752A (en) 1991-08-22 1996-03-12 Daicel Chemical Industries, Ltd. Process for recovering optical isomers and solvent, process for using solvent by circulation and process for reusing optical isomers in optical resolution
EP0630381B1 (en) 1991-10-11 1997-04-09 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral acyclic phosphonomethoxyalkyl substituted, alkenyl and alkynyl purine and pyrimidine derivatives
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
IL106998A0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
US6413949B1 (en) * 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
JPH09506333A (ja) * 1993-09-17 1997-06-24 ギリアード サイエンシーズ,インコーポレイテッド 治療化合物の投薬方法
WO1995007920A1 (en) 1993-09-17 1995-03-23 Gilead Sciences, Inc. Nucleotide analogs
US5656745A (en) * 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
AU707369B2 (en) * 1995-05-26 1999-07-08 Genta Incorporated Compositions and methods for the synthesis of organophosphorus derivatives
US5717095A (en) * 1995-12-29 1998-02-10 Gilead Sciences, Inc. Nucleotide analogs
NZ325704A (en) 1995-12-29 2000-02-28 Gilead Sciences Inc Nucleotide analogs
US5874577A (en) * 1996-04-03 1999-02-23 Medichem Research, Inc. Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
CA2261619C (en) * 1996-07-26 2006-05-23 Gilead Sciences, Inc. Nucleotide analogs
US5739314A (en) 1997-04-25 1998-04-14 Hybridon, Inc. Method for synthesizing 2'-O-substituted pyrimidine nucleosides
ID28006A (id) 1997-07-25 2001-05-03 Gilead Sciences Inc Komposisi analog nukleotida
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
AU756793B2 (en) 1997-07-25 2003-01-23 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
WO1999030727A1 (en) * 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6339151B1 (en) * 1998-01-23 2002-01-15 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
CA2328457A1 (en) * 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6169879B1 (en) * 1998-09-16 2001-01-02 Webtv Networks, Inc. System and method of interconnecting and using components of home entertainment system
GB9821058D0 (en) 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
DE60002986T2 (de) 1999-02-12 2004-05-19 Glaxo Group Ltd., Greenford Phosphoramidat-, mono-, di-, und triphosphatester von (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol als antivirale mittel
IL153658A0 (en) * 2000-07-21 2003-07-06 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US6960648B2 (en) * 2000-10-13 2005-11-01 Universite De Lausanne Intracellular delivery of biological effectors
US20020119433A1 (en) * 2000-12-15 2002-08-29 Callender Thomas J. Process and system for creating and administering interview or test

Also Published As

Publication number Publication date
FR16C0013I1 (fr) 2016-05-27
JP2011140506A (ja) 2011-07-21
NZ536942A (en) 2006-03-31
JP2009062383A (ja) 2009-03-26
SI2682397T1 (sl) 2017-08-31
US20020119443A1 (en) 2002-08-29
AP2003002724A0 (en) 2003-06-30
JP5063554B2 (ja) 2012-10-31
IS2985B (is) 2017-09-15
US7390791B2 (en) 2008-06-24
TR200300055T2 (tr) 2004-12-21
HRP20160074B1 (hr) 2021-09-03
AU2005225039A1 (en) 2005-11-10
US20050159392A1 (en) 2005-07-21
HRP20030047B1 (hr) 2016-02-26
HUP0301307A3 (en) 2005-12-28
AU2005225039B2 (en) 2008-09-25
US7803788B2 (en) 2010-09-28
HU230960B1 (hu) 2019-06-28
HK1243711A1 (en) 2018-07-20
IS6689A (is) 2003-01-17
BE2016C018I2 (pm) 2020-08-20
NL300803I2 (pm) 2016-06-30
IL153658A0 (en) 2003-07-06
NO20131717L (no) 2003-03-20
NO2016006I1 (no) 2016-04-19
EP2682397A1 (en) 2014-01-08
ES2536972T5 (es) 2022-04-06
CA2416757C (en) 2011-02-15
WO2002008241A3 (en) 2002-08-29
NO20030270L (no) 2003-03-20
PT2682397T (pt) 2017-05-31
PL213214B1 (pl) 2013-01-31
CN1291994C (zh) 2006-12-27
EE200300029A (et) 2004-10-15
LTC1301519I2 (lt) 2023-02-27
US20050124585A1 (en) 2005-06-09
US20050124584A1 (en) 2005-06-09
US20060024659A1 (en) 2006-02-02
BG66037B1 (bg) 2010-11-30
CA2893174A1 (en) 2002-01-31
HUS1900027I1 (hu) 2021-03-29
NO2023006I1 (no) 2023-02-03
SI1301519T1 (sl) 2015-07-31
JP5111551B2 (ja) 2013-01-09
KR20030022295A (ko) 2003-03-15
CA2725819C (en) 2015-09-22
CA2416757A1 (en) 2002-01-31
HK1054238A1 (en) 2003-11-21
US20050124583A1 (en) 2005-06-09
HUP0301307A2 (hu) 2003-09-29
HUS000494I2 (hu) 2021-03-29
AU2001282941C1 (en) 2016-12-22
NZ535408A (en) 2006-09-29
HRP20030047A2 (en) 2007-08-31
EP2682397B1 (en) 2017-04-19
NO2016006I2 (no) 2016-04-19
US20050009043A1 (en) 2005-01-13
WO2002008241A2 (en) 2002-01-31
AP1466A (en) 2005-09-22
EE05366B1 (et) 2010-12-15
NO336718B1 (no) 2015-10-26
DK1301519T3 (en) 2015-05-26
US20030219727A1 (en) 2003-11-27
EA004926B1 (ru) 2004-10-28
CZ304734B6 (cs) 2014-09-10
FR16C0013I2 (fr) 2016-09-09
EP1301519A2 (en) 2003-04-16
CZ2003413A3 (cs) 2003-12-17
EA200300188A1 (ru) 2003-06-26
NZ523438A (en) 2005-02-25
AU8294101A (en) 2002-02-05
UA75889C2 (uk) 2006-06-15
CY2016008I2 (el) 2016-12-14
BRPI0112646B8 (pt) 2021-05-25
JP2004504402A (ja) 2004-02-12
CY2016008I1 (el) 2016-12-14
PL360490A1 (en) 2004-09-06
US20080227754A1 (en) 2008-09-18
JP2010174033A (ja) 2010-08-12
JP4651264B2 (ja) 2011-03-16
LU93029I2 (fr) 2016-06-14
BRPI0112646B1 (pt) 2017-10-17
BR0112646A (pt) 2003-06-24
HRP20160074A2 (hr) 2016-03-11
LTPA2016009I1 (lt) 2016-04-25
ES2536972T3 (es) 2015-06-01
CN1706855A (zh) 2005-12-14
NO20120466L (no) 2003-03-20
EP1301519B1 (en) 2015-02-25
PT1301519E (pt) 2015-06-11
CN1443189A (zh) 2003-09-17
KR20060105807A (ko) 2006-10-11
NO20030270D0 (no) 2003-01-20
NO20150909L (no) 2003-03-20
LT2682397T (lt) 2017-06-12
CZ304886B6 (cs) 2015-01-07
CY1119411T1 (el) 2018-03-07
CN100402539C (zh) 2008-07-16
DK2682397T3 (da) 2017-06-19
EP3235823A1 (en) 2017-10-25
EP1301519B2 (en) 2021-11-10
US20040018150A1 (en) 2004-01-29
KR100749160B1 (ko) 2007-08-14
CA2725819A1 (en) 2002-01-31
ZA200210271B (en) 2003-12-31
DK1301519T4 (da) 2021-12-20
HRP20160074A8 (hr) 2016-07-29
BG107572A (bg) 2003-11-28
KR100767432B1 (ko) 2007-10-17
MXPA03000587A (es) 2004-04-05
ES2627903T3 (es) 2017-08-01
AU2001282941B2 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
OA12393A (en) Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.
AU2001282941A1 (en) Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
HK1194074B (en) Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
HK1194074A (en) Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
HK1054238B (en) Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same